Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SXTPW

60 Degrees Pharmaceuticals (SXTPW)

60 Degrees Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SXTPW
DateTimeSourceHeadlineSymbolCompany
02/06/20253:41PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
02/06/20251:07PMGlobeNewswire Inc.60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
02/06/20259:04AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
02/05/20258:22AMGlobeNewswire Inc.60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
01/30/20254:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
01/30/20251:20PMGlobeNewswire Inc.60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
01/30/20257:28AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
01/29/20257:00AMGlobeNewswire Inc.60 Degrees Pharma Announces $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
01/28/20253:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
01/28/20257:01AMGlobeNewswire Inc.60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic BabesiosisNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
01/24/20253:52PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
01/24/20253:51PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
01/21/20254:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
01/21/20253:58PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
01/08/20253:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
01/08/20257:02AMGlobeNewswire Inc.60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) BabesiosisNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
12/23/20247:57AMGlobeNewswire Inc.Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and PreventionNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
12/18/20247:35PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
12/11/20247:56AMGlobeNewswire Inc.60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women’s HospitalNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
12/09/20244:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
11/21/20245:14PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
11/14/20241:31PMGlobeNewswire Inc.60 Degrees Pharmaceuticals Announces Third Quarter 2024 ResultsNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
11/14/202412:44PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
11/06/20244:26PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
10/15/20242:46PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
10/08/20247:17AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
10/03/20248:02AMGlobeNewswire Inc.60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. LaunchNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
10/02/20249:56AMEdgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
09/30/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
09/19/20243:30PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:SXTPW

Your Recent History

Delayed Upgrade Clock